Publication | Open Access

Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome

β-Blocker TherapyHypertensionMarfan SyndromeRandomized Clinical TrialCardiovascular DiseaseAntihypertensive TherapyPharmacologyClinical TrialsCardiovascular PharmacologyPharmacotherapyMedicine